Review ArticleCancer Screening 2016
Introduction
Cancer screening is intended to reduce the number of deaths from cancer and, secondarily, to reduce the incidence of cancer. In accomplishing these goals, the ideal cancer screening test is both sensitive and specific, introduces minimal physical and psychological harm to the patient, detects disease at a preclinical phase and screens for a cancer that has a well-defined treatment. Additionally, the appropriate screening interval for any given testing modality is one where the development of invasive cancer is unlikely before the next screen. At present, the cancers for which screening is performed most often are also the most common and deadlyābreast, cervical, colorectal, lung and prostate cancer.
Section snippets
Breast Cancer
Breast cancer is the most common nondermatologic cancer and the second most common cause of death among women in the United States, with 230,000 cases of invasive disease and nearly 41,000 deaths estimated for 2015.1 Screening is typically performed with digital mammography, which has a sensitivity of 77-95% and a specificity of 94-97%, and which has been associated with a 15-20% reduction in breast cancer mortality.2, 3
Screening guidelines have differed regarding the recommended age to begin
Cervical Cancer
Most emblematic of the success of cervical cancer screening is the fact that approximately half of the cervical cancers diagnosed in the United States occur in women who have never received cytologic screening via Papanicolaou (Pap) testing.19 Cervical cancer is, therefore, a disease that affects primarily women living in low resource, medically underserved areas, where access to cervical cancer screening is not readily available.19
Epidemiologic studies have demonstrated that, although not all
Colorectal Cancer
Colorectal cancer is the third most common cancer and the second leading cause of cancer mortality in the United States.26 Multiple screening modalities have been explored during the last several decades. Among these are stool-based tests, including the guaiac-based fecal occult blood test (FOBT), fecal immunochemical test (FIT) and stool DNA test, endoscopic tests, including rigid and flexible sigmoidoscopy and colonoscopy, and imaging tests, including double-contrast barium enema and computed
Lung Cancer
Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide and carries a 5-year survival rate of only 16.8%.54 Until 2011, the evidence for an effective lung cancer screening tool was lacking, with several trials examining the use of chest radiography, sputum cytology and chest computed tomography, but none demonstrated a mortality benefit.55, 56 However, in August 2011, the National Lung Screening Trial (NLST) changed the screening landscape. In the large,
Prostate Cancer
Prostate cancer is the most commonly diagnosed cancer and the second leading cause of cancer mortality among U.S. men.72 However, the vast majority of men who are diagnosed with prostate cancer do not die of the disease.73 This has led to an intense debate for the past 2 decades over the merit of screening for prostate cancer, particularly with the prostate-specific antigen (PSA) test, which is not cancer-specific.74 The digital rectal examination, often appearing alongside the PSA in screening
Conclusions
The increasing complexity of medical practice has not spared cancer screening. With the advent of new procedural, imaging and laboratory tools, the ability to detect cancer has increased. The characteristics of the ideal cancer screening modality, though, remain the same. The ability to reduce cancer-specific mortality and to detect cancer that is amenable to treatment at a preclinical phase with sensitivity and specificity, while introducing only minimal physical and psychological harm to
References (93)
- et al.
Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years׳ follow-up: a randomized controlled trial
Lancet
(2006) - et al.
A rationale for starting breast cancer screening under age 50
Ann Oncol
(2008) - et al.
Screening interval and risk of invasive squamous cell cervical cancer
Obstet Gynecol
(2003) - et al.
Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice
Lancet Oncol
(2011) - et al.
Randomised controlled trial of faecal-occult-blood screening for colorectal cancer
Lancet
(1996) - et al.
Randomised study of screening for colorectal cancer with faecal-occult-blood test
Lancet
(1996) - et al.
Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer
Eur J Cancer
(2012) - et al.
Participation and yield of colonoscopy versus non-cathartic CT colonography in population-based screening for colorectal cancer: a randomised controlled trial
Lancet Oncol
(2012) - et al.
CT colonography: perforation rates and potential radiation risks
Gastrointest Endosc Clin N Am
(2010) - et al.
Standards for gastroenterologists for performing and interpreting diagnostic computed tomographic colonography
Gastroenterology
(2007)
Racial and ethnic colorectal cancer patterns affect the cost-effectiveness of colorectal cancer screening in the United States
Gastroenterology
The International Epidemiology of Lung Cancer: geographical distribution and secular trends
J Thorac Oncol
The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high risk groups
J Thorac Cardiovasc Surg
The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rottterdam
Eur Urol
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer
J Urol
Mortality results from the Goteborg randomized population-based prostate-cancer screening trial
Lancet Oncol
Early detection of prostate cancer: AUA Guideline
J Urol
Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial
J Urol
Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer
J Urol
Cancer screening in the United States, 2015: a review of current American Cancer Society guidelines and current issues in cancer screening
CA Cancer J Clin
Screening for breast cancer: an update for the U.S. Preventive Services Task Force
Ann Intern Med
American Cancer Society guidelines for breast cancer screening: update 2003
CA Cancer J Clin
Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society
J Am Med Assoc
Screening for breast cancer: U.S. Preventive Services Task Force recommendation statement
Ann Intern Med
Harms of breast cancer screening: systematic review to update the 2009 U.S. Preventive Services Task Force Recommendation
Ann Intern Med
Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study
Ann Intern Med
Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy
JAMA Intern Med
Rate of over-diagnosis of breast cancer 15 years after end of Malmo mammographic screening trial: follow-up study
Br Med J
Canadian National Breast Screening Study-2: 13-year results of a randomized trial in women aged 50-59 years
J Natl Cancer Inst
The Canadian National Breast Screening Study-1: breast cancer mortality after 11 to 16 years of follow-up. A randomized screening trial of mammography in women age 40 to 49 years
Ann Intern Med
Effects of mammography screening under different screening schedules: model estimates of potential benefits and harms
Ann Intern Med
Hanging in the balance: making decisions about the benefits and harms of breast cancer screening among the oldest old without a safety net of scientific evidence
J Clin Oncol
Cancer screening in elderly patients: a framework for individualized decision making
J Am Med Assoc
Human papillomavirus is a necessary cause of invasive cervical cancer worldwide
J Pathol
Sexual behavior and selected health measures: men and women 15-44 years of age, United States, 2000
Adv Data
A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion
J Infect Dis
Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections
J Natl Cancer Inst
American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology Screening Guidelines for the prevention and early detection of cervical cancer
Am J Clin Path
Colorectal cancer statistics, 2014
CA Cancer J Clin
Developments in screening tests and strategies for colorectal cancer
Biomed Res Int
Exposure to colorectal examinations before a colorectal cancer diagnosis: a case-control study
Eur J Gastroenterol Hepatol
Screening colonoscopy and risk for incident late-stage colorectal cancer diagnosis in average-risk adults: a nested case-control study
Ann Intern Med
Protection from colorectal cancer after colonoscopy: a population-based, case control study
Ann Intern Med
Cited by (9)
Electrochemical Biosensor Based on TiO<inf>2</inf> Nanomaterials for Cancer Diagnostics
2018, Advances in Biomembranes and Lipid Self-AssemblyCitation Excerpt :Mammography is used for early detection of breast cancer [13]. Lung and prostate cancer have received attention for regular screening test, where for the lung cancer there are indications that regular screening tests could prevent cancer-related deaths, there is no such confirmation for prostate screening test (with PSA) [39]. Overall, although they have an important impact on prevention, they are accompanied with several downsides.
Patterns of mammography, pap smear, and colorectal cancer screening services among women aged 45 and over
2021, National Health Statistics ReportsPSYCHOLOGICAL SUPPORT FOR GYNECOLOGICAL MALIGNANCIES IN CASES OF FERTILITY PRESERVATION
2021, Fertility Preservation in Gynecological Cancer: Current Management and Novel InsightsGYNECOLOGIC CANCER TREATMENTS AND EFFECTS ON FERTILITY
2021, Fertility Preservation in Gynecological Cancer: Current Management and Novel InsightsQuality of life and fertility preservation counseling for women with gynecological cancer: an integrated psychological and clinical perspective
2020, Journal of Psychosomatic Obstetrics and GynecologyImpacts of isoliquiritigenin on proliferation and apoptosis of human cervical cancer cells
2019, European Journal of Gynaecological Oncology
The authors have no financial or other conflicts of interest to disclose.